ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 979,62
0,28%
Dow Jones
38 675,68
1,18%
DAX
18 074,77
0,45%
Brent Oil
83,465
0,41%
Bitcoin
65 261,42
1,97%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Myriad Genetics Inc (MYGN)

  7. Myriad Genetics Inc (MYGN) Actualités

MYGN Myriad Genetics Inc

19,47
0,00 (0,00%)
Avant marché
Dernière mise à jour : 10:09:44
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Myriad Genetics Inc MYGN NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 19,47 10:09:44
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
19,47
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
30/4/202422:05GLOBEMyriad Genetics to Release First Quarter 2024 Financial..
17/4/202414:00GLOBENearly Half of Americans Say They’ve Lost Time in Their..
16/4/202415:15GLOBENew Myriad Genetics Study Published in Prenatal Diagnosis..
09/4/202414:00GLOBEMyriad Genetics Research Shows Reduction in Hospitalizations..
22/3/202402:40GLOBEMyriad Genetics Announces Foundational Patent Granted for..
20/3/202421:05GLOBEMyriad Genetics Announces Patent Granted for SneakPeek® Snap..
04/3/202422:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202414:31EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202422:05EDGAR2Form 8-K - Current report
27/2/202422:05GLOBEMyriad Genetics Reports Strong Fourth Quarter and Full-Year..
27/2/202415:15GLOBEMyriad Genetics and National Cancer Center Hospital East in..
26/2/202422:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202422:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202422:05GLOBEMyriad Genetics to Release Fourth Quarter and Full Year 2023..
15/2/202422:05GLOBEMyriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as..
14/2/202422:47EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202414:24EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08/2/202416:14EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
01/2/202415:25GLOBEMyriad Genetics Completes Acquisition of Precise Tumor,..
31/1/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/1/202423:00GLOBEMyriad Genetics Names George Daneker Jr., MD, as President..
29/1/202422:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/1/202422:21EDGAR2Form 3 - Initial statement of beneficial ownership of..
23/1/202422:31EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
22/1/202420:03EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
19/1/202400:10GLOBEMyriad Genetics to Acquire Precise Tumor, Precise Liquid and..
16/1/202415:00EDGAR2Form 8-K - Current report
09/1/202422:05GLOBEMyriad Genetics Applauds New Germline Testing Guideline for..
03/1/202422:05GLOBEMyriad Genetics to Present at 42nd Annual J.P. Morgan..
02/1/202423:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/12/202314:30EDGAR2Form 8-K - Current report
21/12/202314:30GLOBEMyriad Genetics Chief Financial Officer Bryan Riggsbee..
20/12/202314:00GLOBEMyriad Genetics Establishes Comprehensive Pan-Cancer..
12/12/202300:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/12/202300:34EDGAR2Form 3 - Initial statement of beneficial ownership of..
05/12/202322:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/11/202322:05GLOBEMyriad Genetics Celebrates One Million SneakPeek® Results..
16/11/202322:05GLOBEMyriad Genetics and Personalis Partner to Market..
13/11/202322:31EDGAR2Form 8-K - Current report
13/11/202312:02EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
09/11/202313:00GLOBEMyriad Genetics to Participate in Stephens Annual Investment..
09/11/202303:20GLOBEMyriad Genetics Announces Pricing of Upsized Offering of..
09/11/202303:16EDGAR2Form 8-K - Current report
08/11/202322:10GLOBEMyriad Genetics Announces Proposed Offering of $100 Million..
08/11/202322:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
08/11/202322:01EDGAR2Form S-3ASR - Automatic shelf registration statement of..
07/11/202314:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202322:05EDGAR2Form 8-K - Current report
06/11/202322:05GLOBEMyriad Genetics Reports Third Quarter 2023 Financial..
03/11/202322:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Dernières Valeurs Consultées

NASDAQ
MYGN
Myriad Genetics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés